$COGT

Cogent Biosciences, Inc.

Runway:8 mo

NasdaqMarket cap: —CIK 0001622229

Upcoming catalysts

1 surfaced

Bezuclastinib · Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

“Based on these top-line data, Cogent expects to submit a new drug application ("NDA") to the U.S. Food and Drug Administration ("FDA") for bezuclastinib in AdvSM during the first half of 2026.”

Date TBD

Drug pipeline

CGT6297

PIK3CA Mutations

Bezuclastinib

Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

ACTR T Cell Product

B Cell Lymphomas

Bezuclastinib Tablets (Formulation A)

SSM

CGT4255

Advanced Solid Tumor, Adult

CGT9486

Gastrointestinal Stromal Tumors

ACTR087

Lymphoma

CGT4859

Intrahepatic Cholangiocarcinoma (Icc)

CGT9486 plus sunitinib

Advanced Gastrointestinal Stromal Tumors

ACTR707

Lymphoma

Recent & active trials

NCT	Drug	Phase	Status	Primary completion
NCT07383506	CGT6297	Phase 1	Not Yet Recruiting	2029-07-01
NCT07361562	CGT4255	Phase 1	Recruiting	2028-05-01
NCT06777316	CGT4859	Phase 2	Active Not Recruiting	2027-03-01
NCT05208047	CGT9486 plus sunitinib	Phase 3	Active Not Recruiting	2025-09-30
NCT04996875	Bezuclastinib	Phase 2	Recruiting	2025-09-19
NCT05186753	Bezuclastinib Tablets (Formulation A)	Phase 2	Active Not Recruiting	2025-05-22
NCT02840110	ACTR T Cell Product	—	Terminated	2020-10-23
NCT03189836	ACTR707	Phase 1	Terminated	2020-09-21
NCT02401815	CGT9486	Phase 2	Completed	2020-05-11
NCT03680560	ACTR T Cell Product	Phase 1	Terminated	2020-03-12
NCT02776813	ACTR087	Phase 1	Completed	2020-02-12
NCT03266692	ACTR087	Phase 1	Terminated	2019-10-01
NCT06948955	Bezuclastinib	—	Available	—
NCT06915766	Bezuclastinib	—	Available	—